Talan-Hranilović J, Gnjidić Z, Sajko T, Vizner B, Vrkljan M
Ljudevit Jurak University Department of Pathology, Sestre Milosrdnice University Hospital, Zagreb, Croatia.
Acta Med Croatica. 2000;54(2):59-63.
The aim of the study was to compare the immunoreactivity of estrogen receptors (ER) and chromogranin-A (CHR-A) in human prolactinomas with verified plurihormonality. Eleven cases of prolactinomas, nine found in women aged from 15-32 and two found in two men both aged 54 years, were analyzed for possible colocalization of other hormones produced by adenohypophysis, i.e. growth hormone (GH), thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and adrenocorticotropic hormone (ACTH). All evaluated cases of prolactinomas were clinically manifested by elevated values of prolactin (PRL) in patient serum, while the values of other assayed hormones were within the normal range. Although biopsy material is not routinely submitted to immunohistochemical analysis for plurihormonality, these eleven cases of operated prolactinomas were randomly examined to the presence of plurihormonality. In six cases of prolactin-producing adenomas, the coexistence of growth hormone was detected. Colocalization of follicle-stimulating hormone and weak expression of adrenocorticotropic hormone were found in two cases each. Thus, bihormonal activity (PRL + GH) was found in six, and trihormonal activity (PRL + GH + FSH and PRL/GH + ACTH) in three cases of prolactinoma. In addition, the presence of prolactin and growth hormone was demonstrated in morphologically different cells. Eight of these eleven pituitary adenomas were tested for estrogen receptors (ER), which play an important role as growth stimulating factors and secretory factors for prolactin-producing cells. We tried to determine if there was a difference in the intensity of expression of estrogen receptors and chromogranin-A between pure prolactinomas and mixed, plurihormonal prolactinomas. By use of monoclonal antibodies, chromogranin-A found to be reactive in seven of eleven prolactinomas, i.e. in plurihormonal prolactinomas. Estrogen receptors were markedly expressed in all the eight prolactinomas analyzed, which may prove significant in the treatment of these hypophyseal tumors.
本研究的目的是比较经证实具有多激素分泌功能的人催乳素瘤中雌激素受体（ER）和嗜铬粒蛋白A（CHR - A）的免疫反应性。分析了11例催乳素瘤病例，其中9例在15 - 32岁的女性中发现，2例在两名均为54岁的男性中发现，以确定腺垂体产生的其他激素，即生长激素（GH）、促甲状腺激素（TSH）、促卵泡激素（FSH）和促肾上腺皮质激素（ACTH）是否可能共定位。所有评估的催乳素瘤病例在临床上均表现为患者血清中催乳素（PRL）值升高，而其他检测激素的值在正常范围内。尽管活检材料通常不会常规进行多激素分泌功能的免疫组化分析，但对这11例手术切除的催乳素瘤进行了随机检查以确定是否存在多激素分泌功能。在6例分泌催乳素的腺瘤病例中，检测到生长激素共存。在2例病例中分别发现了促卵泡激素的共定位和促肾上腺皮质激素的弱表达。因此，在6例催乳素瘤中发现了双激素活性（PRL + GH），在3例催乳素瘤中发现了三激素活性（PRL + GH + FSH和PRL/GH + ACTH）。此外，在形态不同的细胞中证实了催乳素和生长激素的存在。对这11例垂体腺瘤中的8例进行了雌激素受体（ER）检测，雌激素受体作为催乳素分泌细胞的生长刺激因子和分泌因子发挥重要作用。我们试图确定纯催乳素瘤和混合性、多激素分泌性催乳素瘤之间雌激素受体和嗜铬粒蛋白A的表达强度是否存在差异。通过使用单克隆抗体，发现11例催乳素瘤中有7例，即多激素分泌性催乳素瘤中嗜铬粒蛋白A呈反应性。在所分析的所有8例催乳素瘤中雌激素受体均有明显表达，这可能对这些垂体肿瘤的治疗具有重要意义。
